Compare ADMA Biologics Inc (ADMA) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Intuitive Surgical, Inc. — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Intuitive Surgical, Inc. trades at $418.64 (market cap $151.33B). The key difference: Intuitive Surgical, Inc. is far larger — about 71× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | ISRG | |
|---|---|---|
Market Cap | $2.13B | $151.33B |
Sector | Health | Health |
52-Week High | $20.38 | $592.85 |
52-Week Low | $7.60 | $397.68 |
Enterprise Value | $2.20B | $146.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Intuitive Surgical (ISRG) trades at $427.30, up 0.3% on the day, with a bullish technical outlook supported by moving averages and strong support at $422. The company reported robust Q1 2026 earnings of $2.50 per share, beating estimates, and has consistently exceeded expectations. Revenue grew to $10.06 billion in 2025, with a net income margin of 28.15%, though valuation multiples remain elevated with a P/E of 52.59.
The outlook is positive, driven by procedure growth guidance of 13.5-15.5% for 2026 and analyst consensus targeting $565.20. Risks include premium valuation sensitivity and reimbursement challenges in new markets like appendectomy. Institutional sentiment is bullish, with 69% of analysts rating it a buy, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
